C
Chengcan Yang
Researcher at Shanghai Jiao Tong University
Publications - 11
Citations - 85
Chengcan Yang is an academic researcher from Shanghai Jiao Tong University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 3, co-authored 6 publications receiving 28 citations.
Papers
More filters
Journal ArticleDOI
Improvement in Nocturnal Hypoxemia in Obese Patients with Obstructive Sleep Apnea after Bariatric Surgery: a Meta-Analysis
TL;DR: Bariatric surgery is effective at improving nocturnal hypoxemia in obese patients with OSA; it also reduces body weight and the number of apnea events and the potential underlying mechanisms are explored.
Journal ArticleDOI
Main active components of Si-Miao-Yong-An decoction (SMYAD) attenuate autophagy and apoptosis via the PDE5A-AKT and TLR4-NOX4 pathways in isoproterenol (ISO)-induced heart failure models
TL;DR: In this paper , the main active components of Si-Miao-Yong-An decoction (SMYAD) were identified based on UL-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (UPLCQ/TOF-MS) results.
Journal ArticleDOI
Transplantation of neuregulin 4-overexpressing adipose-derived mesenchymal stem cells ameliorates insulin resistance by attenuating hepatic steatosis.
TL;DR: ADC transplantation improves glucose tolerance and metabolic balance in HFD-fed mice by multiple mechanisms, including upregulating GLUT4 expression and suppressing inflammation, and Nrg4 overexpression could improve the efficacy of ADSCs in ameliorating insulin resistance (IR) and other obesity-related metabolic disorders.
Journal ArticleDOI
Targeting Bromodomain-Selective Inhibitors of BET Proteins in Drug Discovery and Development.
Juncheng Chen,Pan Tang,Yuxi Wang,Jiaxing Wang,Chengcan Yang,Yang Li,Gaoxia Yang,Fengbo Wu,Jifa Zhang,Liang Ouyang +9 more
TL;DR: It is illustrated that some BET bromodomain (BET-BD1 or BET-BD2)-selective inhibitors have advantage over pan-inhibitors, including reduced toxicity concerns, and the methods for enhancing the selectivity and potency of these inhibitors based on their different modes of interactions.
Journal ArticleDOI
Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.
Jifa Zhang,Chengcan Yang,Pan Tang,Juncheng Chen,Dan Zhang,Yang Li,Gaoxia Yang,Yun Liu,Yiwen Zhang,Yuxi Wang,Jie Liu,Liang Ouyang +11 more
TL;DR: This strategy aims to expand the use of PARPi in BRCA-competent TNBC, making an innovative approach to address unmet oncology needs and optimized the BRD4-PARP1 inhibitor based on previous studies.